United States: Trump Executive Orders Create Uncertainty For Health Care & Pharmaceutical Industries

As we've previously discussed on Health Law and Policy Matters, agencies within the Department of Health and Human Services (DHHS) pushed through several final rules towards the end of the Obama Administration (see here and here). However, since taking office, President Trump has followed through on his campaign promise to significantly roll back Federal regulations and has taken several actions aimed at slowing and reversing agency regulatory processes, including processes at the DHHS sub-agencies CMS and FDA. These executive actions are creating a climate of uncertainty for regulated industries and their stakeholders.

What Actions Have Been Taken Pursuant to Trump's "Regulatory Reform" Agenda?

  • On Inauguration Day, new Chief of Staff Reince Priebus issued a memorandum that announced a freeze on the issuance of any new or pending regulations or guidance documents by Federal departments and agencies. This order also required agencies to postpone the effective date of any final rules that were already published but not yet in effect, so that they could be reviewed by appointees of the Trump Administration.
  • Then on January 30th, the President signed his so-called "2-for-1" Executive Order (formally called the "Executive Order on Reducing Regulation and Controlling Regulatory Costs"), which requires Federal agencies to identify at least two existing regulations to be repealed when proposing or implementing a new one. It also requires agencies to have a zero incremental cost increase for regulations finalized in fiscal year 2017.
  • The White House Office for Management and Budget (OMB) issued interim guidance on February 2, 2017 that clarifies certain aspects of implementing the 2-for-1 Order. Most critically, OMB clarified that (i) the Order applies only to regulatory actions classified as "significant"; (ii) agency guidance documents may be impacted as well if they rise to the level of being "significant"; and (iii) any existing regulatory action that may produce "verifiable savings" upon its repeal may qualify as a deregulatory action for purposes of the 2-for-1 Order. In order to be deemed "significant," a regulation must have an annual effect of $100 million or more on the U.S. economy or adversely affect the economy in some material way, among other possibilities.
  • On February 24, 2017, President Trump issued another Executive Order that requires each Federal agency to establish a task force headed by a Regulatory Reform Officer to review its existing regulations and work towards meeting the Administration's various policy goals. These Regulatory Reform Task Forces are required to provide their first progress report to their respective agency heads within 90 days (so by May 25, 2017).

The 2-for-1 Order and OMB's interim guidance were quickly challenged by public interest groups in a lawsuit that alleges the actions exceed the executive's constitutional authority and violate the Take Care Clause. The lawsuit is pending in the D.C. District Court.

How Are DHHS Agencies Being Affected?

Highly regulated industries like those in the health care and drug development spaces are faced with significant uncertainty about how new rules may be implemented as well as which old rules may be repealed in order to meet President Trump's cost-cutting mandates. Indeed, the OMB's interim guidance on the 2-for-1 Order does not address all of the uncertainties, and we would expect some additional guidance from that office soon in light of the "interim" label on that February 2nd document (OMB accepted comments on it through February 10th).

But until such a time that agencies and the public have a better understanding of the intricacies of these inter-related executive orders and White House memoranda, affected stakeholders may have a difficult time predicting the fate of proposed or existing regulations. Several important questions remain:

  • The 2-for-1 Order applies by its terms even to regulations explicitly required by statute. However, per the OMB's clarifications, the order does allow regulations issued under a statutory or judicial deadline to be enacted without the agency being required to identify the two corresponding regulations for repeal "by the time of issuance." Some of the issues that continue to be unclear include (i) when the required "offsetting regulatory actions" would need to be identified or actually repealed; (ii) what the consequences are, if any, to an agency that does not complete the offsetting process; and (iii) what happens to the new regulation that was promulgated if the agency doesn't follow through. The February 24, 2017 Executive Order on "Enforcing the Regulatory Reform Agenda" includes a provision on agency accountability, but OMB has not yet released any guidelines for such accountability metrics.
  • In interpreting the 2-for-1 Order's requirement that every new and repealed regulation be scored for its economic impact/cost savings, the OMB interim guidance explains that all previous economic impact analyses are presumed to be inaccurate and must to be revised. Accordingly, the cost of current and future regulations may be more heavily scrutinized than before. This is expected to create a greater burden on agencies like CMS and FDA to perform economic analyses that they are not necessarily heavily staffed to do; and hiring additional economists may not be possible under the Administration's civilian hiring freeze (there is no obvious exemption for economists under a DHHS implementation memo on the hiring freeze, dated February 6th).
  • The OMB interim guidance makes clear that formal notice-and-comment rulemaking is not the only regulatory activity affected by these executive orders – agency guidance documents may be impacted as well if they rise to the level of being "significant." More specifically, OMB states that informal guidance documents "will be addressed on a case-by-case basis" and that "any cost savings claims for guidance or other documents must be specific and verifiable." Agencies like FDA heavily rely on guidance documents as a way to elucidate the expectations for regulated industry, especially in technical areas, and industry stakeholders also appreciate the clarity that guidance documents can provide. So it remains an open question whether FDA, among other agencies, will have to withdraw two existing guidance documents before it can issue a new one.

For health care and related industries in which the regulatory scheme is very tightly knit and far-reaching in scope, agencies will have to take great care in determining which regulations should be on the chopping block to offset new ones. The interwoven nature of many regulations makes it very difficult to remove one piece without having a major impact on other areas. Such complex decision-making processes also could cause a slowdown in activity by agencies that some stakeholders feel already have very protracted rulemaking timelines and do not move quickly enough to respond to emerging issues.

We will continue to watch the effect of these important executive orders on the health care, pharmaceutical, and medical device industries. We also continue to monitor Congress for actions that may be taken under the Congressional Review Act to overturn final regulations implemented by the Obama Administration. Stay tuned for updates and specific reports on FDA, CMS, or other DHHS activities that might be curtailed or rolled back.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions